<?xml version='1.0' encoding='utf-8'?>
<document id="17186001"><sentence text="Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects."><entity charOffset="0-9" id="DDI-PubMed.17186001.s1.e0" text="Lopinavir" /><entity charOffset="10-19" id="DDI-PubMed.17186001.s1.e1" text="ritonavir" /><entity charOffset="28-37" id="DDI-PubMed.17186001.s1.e2" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.17186001.s1.e0" e2="DDI-PubMed.17186001.s1.e0" /><pair ddi="false" e1="DDI-PubMed.17186001.s1.e0" e2="DDI-PubMed.17186001.s1.e1" /><pair ddi="false" e1="DDI-PubMed.17186001.s1.e0" e2="DDI-PubMed.17186001.s1.e2" /><pair ddi="false" e1="DDI-PubMed.17186001.s1.e1" e2="DDI-PubMed.17186001.s1.e1" /><pair ddi="false" e1="DDI-PubMed.17186001.s1.e1" e2="DDI-PubMed.17186001.s1.e2" /></sentence><sentence text="Limited data are available about the effect of steady-state lopinavir and ritonavir (LPV/r) on bupropion pharmacokinetics"><entity charOffset="60-69" id="DDI-PubMed.17186001.s2.e0" text="lopinavir" /><entity charOffset="74-83" id="DDI-PubMed.17186001.s2.e1" text="ritonavir" /><entity charOffset="85-88" id="DDI-PubMed.17186001.s2.e2" text="LPV" /><entity charOffset="95-104" id="DDI-PubMed.17186001.s2.e3" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.17186001.s2.e0" e2="DDI-PubMed.17186001.s2.e0" /><pair ddi="false" e1="DDI-PubMed.17186001.s2.e0" e2="DDI-PubMed.17186001.s2.e1" /><pair ddi="false" e1="DDI-PubMed.17186001.s2.e0" e2="DDI-PubMed.17186001.s2.e2" /><pair ddi="false" e1="DDI-PubMed.17186001.s2.e0" e2="DDI-PubMed.17186001.s2.e3" /><pair ddi="false" e1="DDI-PubMed.17186001.s2.e1" e2="DDI-PubMed.17186001.s2.e1" /><pair ddi="false" e1="DDI-PubMed.17186001.s2.e1" e2="DDI-PubMed.17186001.s2.e2" /><pair ddi="false" e1="DDI-PubMed.17186001.s2.e1" e2="DDI-PubMed.17186001.s2.e3" /><pair ddi="false" e1="DDI-PubMed.17186001.s2.e2" e2="DDI-PubMed.17186001.s2.e2" /><pair ddi="false" e1="DDI-PubMed.17186001.s2.e2" e2="DDI-PubMed.17186001.s2.e3" /></sentence><sentence text=" As patients may benefit by using these two agents in combination, this study determined the extent and direction of this drug-drug interaction" /><sentence text=" Twelve healthy volunteers received a single 100 mg dose of sustained-release bupropion before and after 2 weeks of treatment with LPV/r 400 mg/100 mg twice daily"><entity charOffset="78-87" id="DDI-PubMed.17186001.s4.e0" text="bupropion" /><entity charOffset="131-139" id="DDI-PubMed.17186001.s4.e1" text="LPV" /><pair ddi="false" e1="DDI-PubMed.17186001.s4.e0" e2="DDI-PubMed.17186001.s4.e0" /><pair ddi="false" e1="DDI-PubMed.17186001.s4.e0" e2="DDI-PubMed.17186001.s4.e1" /></sentence><sentence text=" Pharmacokinetics profiles were determined on days 1 and 30 for bupropion and hydroxybupropion and days 29 and 30 for LPV/r"><entity charOffset="64-73" id="DDI-PubMed.17186001.s5.e0" text="bupropion" /><entity charOffset="78-94" id="DDI-PubMed.17186001.s5.e1" text="hydroxybupropion" /><entity charOffset="118-133" id="DDI-PubMed.17186001.s5.e2" text="LPV" /><pair ddi="false" e1="DDI-PubMed.17186001.s5.e0" e2="DDI-PubMed.17186001.s5.e0" /><pair ddi="false" e1="DDI-PubMed.17186001.s5.e0" e2="DDI-PubMed.17186001.s5.e1" /><pair ddi="false" e1="DDI-PubMed.17186001.s5.e0" e2="DDI-PubMed.17186001.s5.e2" /><pair ddi="false" e1="DDI-PubMed.17186001.s5.e1" e2="DDI-PubMed.17186001.s5.e1" /><pair ddi="false" e1="DDI-PubMed.17186001.s5.e1" e2="DDI-PubMed.17186001.s5.e2" /></sentence><sentence text=" LPV/r administration significantly decreased bupropion maximum plasma concentration (C(max)) by 57% (90% confidence interval (CI), 38-76%; P&lt;0"><entity charOffset="46-55" id="DDI-PubMed.17186001.s6.e0" text="bupropion" /><entity charOffset="1-9" id="DDI-PubMed.17186001.s6.e1" text="LPV" /><pair ddi="false" e1="DDI-PubMed.17186001.s6.e1" e2="DDI-PubMed.17186001.s6.e1" /><pair ddi="false" e1="DDI-PubMed.17186001.s6.e1" e2="DDI-PubMed.17186001.s6.e0" /></sentence><sentence text="01) and area under the curve (AUC) infinity by 57% (90% CI, 32-83%; P&lt;0" /><sentence text="01)" /><sentence text=" Hydroxybupropion C(max) and AUC infinity decreased by 31% (90% CI, 7-55%; P&lt;0" /><sentence text="01) and by 50% (90% CI, 34-65%; P&lt;0" /><sentence text="01), respectively" /><sentence text=" No significant changes in the pharmacokinetics of LPV/r were found following administration of a single dose of bupropion"><entity charOffset="113-122" id="DDI-PubMed.17186001.s12.e0" text="bupropion" /><entity charOffset="51-59" id="DDI-PubMed.17186001.s12.e1" text="LPV" /><pair ddi="false" e1="DDI-PubMed.17186001.s12.e1" e2="DDI-PubMed.17186001.s12.e1" /><pair ddi="false" e1="DDI-PubMed.17186001.s12.e1" e2="DDI-PubMed.17186001.s12.e0" /></sentence><sentence text=" Concurrent use of LPV/r and bupropion resulted in decreased exposure to bupropion and its active metabolite hydroxybupropion that may necessitate as much as a 100% dose increase of bupropion"><entity charOffset="29-38" id="DDI-PubMed.17186001.s13.e0" text="bupropion" /><entity charOffset="73-82" id="DDI-PubMed.17186001.s13.e1" text="bupropion" /><entity charOffset="182-191" id="DDI-PubMed.17186001.s13.e2" text="bupropion" /><entity charOffset="19-27" id="DDI-PubMed.17186001.s13.e3" text="LPV" /><pair ddi="false" e1="DDI-PubMed.17186001.s13.e3" e2="DDI-PubMed.17186001.s13.e3" /><pair ddi="false" e1="DDI-PubMed.17186001.s13.e3" e2="DDI-PubMed.17186001.s13.e0" /><pair ddi="false" e1="DDI-PubMed.17186001.s13.e3" e2="DDI-PubMed.17186001.s13.e1" /><pair ddi="false" e1="DDI-PubMed.17186001.s13.e3" e2="DDI-PubMed.17186001.s13.e2" /><pair ddi="false" e1="DDI-PubMed.17186001.s13.e0" e2="DDI-PubMed.17186001.s13.e0" /><pair ddi="false" e1="DDI-PubMed.17186001.s13.e0" e2="DDI-PubMed.17186001.s13.e1" /><pair ddi="false" e1="DDI-PubMed.17186001.s13.e0" e2="DDI-PubMed.17186001.s13.e2" /><pair ddi="false" e1="DDI-PubMed.17186001.s13.e1" e2="DDI-PubMed.17186001.s13.e1" /><pair ddi="false" e1="DDI-PubMed.17186001.s13.e1" e2="DDI-PubMed.17186001.s13.e2" /></sentence><sentence text=" A probable mechanism for this interaction is the concurrent induction of cytochrome P450 2B6 and UDP-glucuronosyltransferase enzymes" /><sentence text=" LPV/r exposure is unaffected by a single dose of bupropion"><entity charOffset="50-59" id="DDI-PubMed.17186001.s15.e0" text="bupropion" /><entity charOffset="1-9" id="DDI-PubMed.17186001.s15.e1" text="LPV" /><pair ddi="false" e1="DDI-PubMed.17186001.s15.e1" e2="DDI-PubMed.17186001.s15.e1" /><pair ddi="false" e1="DDI-PubMed.17186001.s15.e1" e2="DDI-PubMed.17186001.s15.e0" /></sentence><sentence text="" /></document>